Kenneth Smith, Ph.D.
Research Associate Member
Arthritis & Clinical Immunology Research Program
Research
Our lab’s goal is the discovery and characterization of full length, fully human monoclonal antibodies cloned from single B cells after vaccination. We explore the use of these antibodies as novel therapeutics and diagnostics for infectious agents and also elucidate the B cell immunology which leads to these antibodies and the biology of the B cells that make them. Our primary focus is antibodies that bind to polysaccharide antigens, specifically from the Streptococcus pneumoniae (SPN) capsule. We are working to use these antibodies as novel treatments for severe pneumonia, as well as for diagnostics to both diagnose SPN infections and explore the epidemiology of SPN, for example, the distribution of antibiotic resistant and non-vaccine serotypes. We also have active projects producing and characterizing antibodies to anthrax toxins and rabies virus.
We are developing new methods for characterizing monoclonal antibodies from patients with systemic lupus erythematosus. We are working to better understand the B cell immunology that leads to autoantibody production, epitope spreading and affinity maturation.
We also explore aspects of general B cell immunology, including Vgene, light chain and isotype usage in immune responses to vaccination, infection, allergy and autoimmunity. Finally, we produce highly engineered antibody formats, such as bispecific antibodies and antibody-drug conjugates.
Publications
Recent Publications
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc 4:372-84, 2009 January, PMID: 19247287, PMCID: PMC2750034
Jaiswal S, Smith K, Ramirez A, Woda M, Pazoles P, Shultz LD, Greiner DL, Brehm MA, Mathew A. Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) 240:67-78, 2015 January, PMID: 25125497, PMCID: PMC4446989
Kaur K, Zheng NY, Smith K, Huang M, Li L, Pauli NT, Henry Dunand CJ, Lee JH, Morrissey M, Wu Y, Joachims ML, Munroe ME, Lau D, Qu X, Krammer F, Wrammert J, Palese P, Ahmed R, James JA, Wilson PC. High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination. PLoS One 10:e0125618, 2015 May, PMID: 25951191, PMCID: PMC4423960
Selected Publications
Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008 May 29; 453(7195): 667-71.
Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, Wilson PC. Rapid generation of fully human monoclonal antibodies specific to a vaccinating agent. Nat Protoc. 2009; 4(3): 372-84.
Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, Zheng NY, Farris AD, Guthridge JM, Wilson PC, James JA. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine. 2012; 30(28):4276-83.
Smith K, Muther JJ, Duke AL, McKee E, Zheng NY, Wilson PC, James JA. Fully human monoclonal antibodies from antibody secreting cells after vaccination with pneumovax23 are serotype specific and facilitate opsonophagocytosis. Immunobiology. 2013; 218(5):745-54.
Smith K, Shah H, Muther JJ, Duke AL, Haley K, James JA. Antigen nature and complexity influence human antibody light chain usage and specificity. Vaccine 2016; 34(25):2813-20.
Contact
Arthritis & Clinical Immunology Research Program, MS 5
Oklahoma Medical Research Foundation
825 N.E. 13th Street
Oklahoma City, OK 73104
Phone: (405) 271-3275
Fax: (405) 271-3980
E-mail: Ken-Smith@omrf.org